TKTerezia Kickova

Terezia Kickova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Terezia Kickova has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Daniela Gasperikova

    Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia

    3 shared publications
  • Martina Skopkova

    Diabgene Laboratory, Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences

    3 shared publications
  • Juraj Stanik

    Department of Paediatrics, Medical Faculty of the Comenius University and National Institute for Children’s Diseases, Slovakia

    2 shared publications
  • Diana Ugorova

    Department of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine, Comenius University in Bratislava and University Hospital Bratislava, Bratislava, Slovakia

    1 shared publication
  • Gabriela Lackova

    Outpatient Clinic of Diabetology, Metabolic Disorders and Nutrition, Policlinic SANAT Levice Slovakia

    1 shared publication
  • Juraj Stanik

    DIABGENE Laboratory, Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia

    1 shared publication

Latest Publications

  • Open Access

    Screening for Maternally Inherited Diabetes and Deafness in Large Cohorts of Hearing Impaired and Diabetic Patients

    by Lukas Varga, Silvia Borecka, Martina Skopkova, Vibhuti Rambani, Marek Sklenar, Klaudia Cipkova, Terezia Kickova, Diana Ugorova, Zuzana Kabatova, Juraj Stanik, et al.

    Objectives: Mitochondrial DNA (mtDNA) mutations account for up to 5% of hereditary hearing loss cases. Most commonly, the m.3243A>G mtDNA variant contributes to rare monogenic MIDD (Maternally Inherited Diabetes and Deafness) or MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) syndromes. Different proportions of the mutated mtDNA (heteroplasmy) among the affected tissues result in variability in the clinical manifestation and severity of the phenotype. The aim of the presented study was to establish the prevalence of the m.3243A>G variant in large cohorts of hearing-impaired and diabetic patients in Slovakia and to evaluate the genotype-phenotype correlations and long-term cochlear implantation outcomes. Design: Probands (n=5957) were recruited via three independent nationwide studies on hereditary hearing loss (n=1145) and diabetes (unselected diabetes group, n=4158 and Monogenic diabetes group, n=654; total n=4812). DNA from peripheral blood and/or buccal mucosa was tested for the presence of the m.3243A>G variant using two PCR methods – qPCR and dPCR. Audiological and other clinical data of the identified variant carriers were also collected for phenotype evaluation. Results: We identified 25 probands/families harboring the m.3243A>G variant (0.42%). The prevalence was higher in the groups where monogenic disorder was suspected – 0.79% in the Hearing loss group and 1.68% in the Monogenic diabetes group versus 0.14% in the general diabetes group ( p < 0.001). Heteroplasmy levels assessed by dPCR ranged between 0.04% and 76% in peripheral blood and 0.01% and 92% in buccal samples. In most individuals, the symptoms manifested in the fourth decade of life in affected subjects with the MIDD phenotype or isolated hearing loss/diabetes, but as early as in the second decade in the probands with MELAS. We observed high phenotype variability, ranging from severe multisystemic involvement through isolated symptoms to asymptomatic young “dormant” or very low heteroplasmy carriers. Only 54% of individuals with the m.3243A>G variant had both diabetes and hearing loss. The heteroplasmy levels from buccal swabs showed a better correlation with the age of onset of both hearing loss and diabetes than the age-adjusted blood heteroplasmy. On the other hand, the age-adjusted blood heteroplasmy was associated with overall severity of the disease (i.e., with a higher number of clinical symptoms). We show that the most typical audiogram configurations are flat and sloping. Three individuals identified as cochlear implant recipients showed excellent and long-term stable functional outcomes. In addition, the authors report the first case of successful stapes surgery in a patient with confirmed mitochondrial disorder. Conclusions: The diagnostic yield was higher in the deafness and monogenic diabetes groups than in the unselected diabetes group. Implementation of rigorous inclusion criteria requiring the presence of both diabetes and hearing loss may lead to a lower detection rate due to different or incomplete phenotype manifestation. Age-adjusted blood heteroplasmy levels seem to be a good predictor of overall severity of m.3243A>G-associated diseases, but buccal mucosa heteroplasmy better predicted the age of hearing loss and diabetes onset. We further confirm that cochlear implantation and stapedectomy are safe and efficient options for hearing restoration and rehabilitation in m.3243A>G carriers.

  • An alternative approach using hs‐CRP levels and age of onset in diagnostics of HNF1A‐MODY

    by Terezia Kickova, Martina Skopkova, Zuzana Dobiasova, Gabriela Lackova, Zita Belicova, Katarina Schenkova, Juraj Stanik, Daniela Gasperikova

    Aims: The aim is to identify people with HNF1A‐MODY among individuals in diabetic cohort solely based on low hs‐CRP serum level and early diabetes onset.Methods: In 3537 participants, we analyzed the hs‐CRP levels. We analyzed the HNF1A gene in 50 participants (1.4% of the cohort) with type 1 or type 2 diabetes who had hs‐CRP ≤0.25 mg/L and were diagnosed with diabetes mellitus (DM) at the age of 8–40 years. We functionally characterized two identified missense variants.Results: Three participants had a rare variant in the HNF1A gene, two of which we classified as likely pathogenic: c.1369_1384dup (p.Val462Aspfs*92) and c.737T>G (p.Val246Gly), and one as likely benign: c.1573A>T (p.Thr525Ser). Our functional studies revealed that p.Val246Gly decreased HNF1α transactivation activity to ~59% and the DNA binding ability to ~16% of the wild‐type, while p.Thr525Ser variant showed no effect on transactivation activity, DNA binding, nor nuclear localization. Based on the two identified HNF1A‐MODY patients among 3537 people with diabetes, we estimate 0.057% as the minimal HNF1A‐MODY prevalence in Slovakia. A positive predictive value of hs‐CRP ≤0.25 mg/L for finding HNF1A‐MODY individuals was 4.0% (95% CI 0.7%, 13.5%).Conclusions: Hs‐CRP value and age of DM onset could be an alternative approach to current diagnostic criteria with a potential to increase the diagnostic rate of HNF1A‐MODY.


  • Open Access

    Novel insights into genetics and clinics of the HNF1A-MODY

    by Terezia Valkovicova, Martina Skopkova, Juraj Stanik, Daniela Gasperikova

    MODY (Maturity Onset Diabetes of the Young) is a type of diabetes resulting from a pathogenic effect of gene mutations. Up to date, 13 MODY genes are known. Gene HNF1A is one of the most common causes of MODY diabetes (HNF1A-MODY; MODY3). This gene is polymorphic and more than 1200 pathogenic and non-pathogenic HNF1A variants were described in its UTRs, exons and introns. For HNF1A-MODY, not just gene but also phenotype heterogeneity is typical. Although there are some clinical instructions, HNF1A-MODY patients often do not meet every diagnostic criteria or they are still misdiagnosed as type 1 and type 2 diabetics. There is a constant effort to find suitable biomarkers to help with in distinguishing of MODY3 from Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D). DNA sequencing is still necessary for unambiguous confirmation of clinical suspicion of MODY. NGS (Next Generation Sequencing) methods brought discoveries of multiple new gene variants and new instructions for their pathogenicity classification were required. The most actual problem is classification of variants with uncertain significance (VUS) which is a stumbling-block for clinical interpretation. Since MODY is a hereditary disease, DNA analysis of family members is helpful or even crucial. This review is updated summary about HNF1A-MODY genetics, pathophysiology, clinics functional studies and variant classification.